Ghayas Issa
@GhayasIssa
Followers
783
Following
109
Media
4
Statuses
153
Leukemia Physician at MD Anderson. Research in AML, CML, other leukemias if it's the right genotype. Views expressed here are my own.
Joined April 2017
Surreal to play a role in this relay race. Below proof that menin inhibition works. A new targeted therapy in leukemia published @Nature
https://t.co/SQQwgh6GzV
@MDAndersonNews
nature.com
Nature - Revumenib, a potent and selective oral inhibitor of the menin–KMT2A interaction, is associated with a low frequency of treatment-related adverse events and promising clinical...
30
71
253
Menin inhibitors emerge as new treatment for advanced AML. Guest editorial by Ghayas Issa (@GhayasIssa, @MDAndersonNews). https://t.co/2m0swajbbf
cancerletter.com
The world of cancer treatments continues to evolve, and for those diagnosed with blood cancers, a new option can be found in menin inhibitors—the latest form of targeted therapy in advanced acute...
0
5
15
"Our research confirmed the significant benefits and efficacy of this therapy for both adult and pediatric patients," says Dr. Ghayas Issa. @US_FDA has approved revumenib for some patients with relapsed or refractory acute leukemia: https://t.co/NywVWKNzPS
@GhayasIssa #EndCancer
1
13
44
Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)
11
38
184
We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration
@GhayasIssa @MDAndersonNews
0
4
9
The first BTC trial to target AML MRD with combination of menin and BCL2 inhibition is now open! Huge team effort and more exciting trials for MRD to come. Goal is to better measure, understand and treat MRD
We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration
@GhayasIssa @MDAndersonNews
4
12
51
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute #Leukemia (AUGMENT-101): https://t.co/3l9oeqhvDS
#leusm
ascopubs.org
PURPOSERevumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study of heavily pretreated...
0
5
8
Revumenib phase 2 for R/R KMT2Ar finally out! ORR 63%, CR/CRh 23%, MRD neg 70%. Result filed for FDA approval https://t.co/Ry3fUflfQ3
ascopubs.org
PURPOSERevumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study of heavily pretreated...
8
44
113
How long do you wait for leukemia fusion RT-PCR, FISH, cytogenetics? Bedside CRISPR-based detection of PML::RARA and BCR::ABL1 fusions as a point of care test, even on a dried blood spot, from #RahulVedula and @ColemanLindsley @DanaFarber #HemeNeoDivision
ashpublications.org
Key PointsSHERLOCK is 100% sensitive and specific for the diagnosis of APL and CML in patient samples.SHERLOCK has the potential to improve access to life-
2
11
48
A pleasure to do this on differentiation syndrome with Eytan and Courtney. A thread 🧵 https://t.co/5vJhvDBkaG
ashpublications.org
Treatment for patients with acute myeloid leukemia (AML) is being transformed for some patients, as targeted agents increase complete remission rates and s
2
12
64
Menin inhibitors seek to debut as newest targeted therapy for leukaemia https://t.co/4Y3CgAkyrs Find out how small molecules that block a key protein–protein interaction could change the treatment landscape for many patients with acute leukaemias in this news article
0
4
11
👉👉Delighted to present results of an investigator-initiated trial of Pirto + Ven + Obin as firstline Rx of pts with #CLL at @EHA_Hematology #EHA2024 A thread 🧵
3
16
75
Asciminib frontline!
Presented at #ASCO24: ASC4FIRST: Asciminib, an agent that targets the myristoyl pocket of BCR::ABL, was compared with imatinib and with imatinib plus second-generation tyrosine kinase inhibitors. Outcomes were better with aciminib in both comparisons. https://t.co/PMPF00jUjF
0
5
22
Nice! Congrats @DavidSeoMD!! Forgive you for missing eclipse events :)
Watch author @DavidSeoMD discuss his research article, Randomized phase 1b microbiome modulation trial in #melanoma, published simultaneously at #AACR24: https://t.co/298dQ5LEOS
@MDAndersonNews
1
0
3
Watch author @DavidSeoMD discuss his research article, Randomized phase 1b microbiome modulation trial in #melanoma, published simultaneously at #AACR24: https://t.co/298dQ5LEOS
@MDAndersonNews
Just published with the #AACR24 presentation, by @DavidSeoMD— Randomized Placebo-Controlled, Biomarker-stratified Phase 1b #Microbiome Modulation in #Melanoma: Impact of Antibiotic Pre-conditioning. https://t.co/6mNN5SJkA3
@CSpencerPhD @JenWargoMD @MDAndersonNews
0
3
4
Wonderful editorial by Dr Bernt on Barajas et al showing the latest addition to the “club”. Eytan and I have been brewing this trial for a while and it’s finally about to open: menin inhibition for the HOX-high club (including UBTF-TD based on this work) https://t.co/t66awONeqj
1
2
17
0
0
5
Menin inhibitors continue to show tremendous promise in AML w/ encouraging clinical activity as single agents and now in comb. w/ HMA’s + Ven in R/R AML w/ NPM1 or KMT2Ar. Great presentation by @GhayasIssa on SAVE trial. Hopeful these agents will make a huge impact in AML. #ASH23
0
11
46
Revumenib Combo Showcases Early Activity in Relapsed/Refractory AML @GhayasIssa @MDAndersonNews @ASH_Hematology #ASH23 #ASH2023 #leusm
onclive.com
Revumenib, decitabine/cedazuridine, plus venetoclax elicited an objective response rate of 100% with acceptable safety in patients with relapsed/refractory acute myeloid leukemia enrolled in the...
1
1
10